1251838-36-4

Upstream product

• 4876-59-9 4-(dimethylamino)piperidine dihydrochloride 
• 122-04-3 4-nitro-benzoyl chloride 
• 50533-97-6 dimethyl-piperidin-4-yl-amine 

Downstream Products

• 50534-08-2 (4-aminophenyl)(4-(dimethylamino)piperidin-1-yl)methanone 

Relevant academic research and scientific papers

Gedatolisib intermediates for preparation of (by machine translation)

The invention belongs to the organic synthesis and bulk drug intermediate preparation field, in particular to a method for preparing Gedatolisib, key intermediate and a key intermediate in the preparation method. The nitrobenzene nitrile and dicyanodiamine polyisobutylene triazine cyclization, morpholine link guan huan, hydrogenation of nitro reduction to obtain 4 - (4, 6 - II morpholino - 1, 3, 5 - triazine - 2 - yl) aniline; 4 - oxo-piperidine - 1 - carboxylic acid tert-butyl and dimethylamine salt by addition, de-Boc protecting group, amide, hydrogenation of nitro reduction to get new compounds (4 - aminophenyl) (4 - (dimethyl amino) piperidine - 1 - yl) methyl ketone; adopts the one-pot synthesis, (4, 6 - II morpholino - 1, 3, 5 - triazine - 2 - yl) aniline and chloromethane acid ester after the reaction, then adding (4 - aminophenyl) (4 - (dimethyl amino) piperidine - 1 - yl) methanone, to finally obtain the Gedatolisib. This preparation method has the advantages of easy availability of raw materials, process is simple, easy to operate, high yield and low cost and the like. (by machine translation)

5, 6, 7, 8-TETRAHYDROPYRIDO[4,3-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR, PI3, AND HSMG-1 KINASE INHIBITORS, AND THEIR SYNTHESES

A compound of the Formula I: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.